External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Inflammatory Disease UEGW 2024
Roche and Genentech at

UEGW 2024

October 12 - October 15
Vienna, Austria / Virtual (Hybrid)
ueg.eu
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
08:24 AM
Duration 12mins Vienna, Austria
Efficacy and safety of RO7790121, a fully human monoclonal antibody blocking tumour necrosis factor-like ligand 1A in moderately to severely active ulcerative colitis: Results from the randomised, double-blind, placebo-controlled, dose-ranging phase 2b TUSCANY-2 study
Danese S, Allegretti JR, Schreiber S, Peyrin-Biroulet L, Jairath V, D'Haens G, Kierkus J, Leong RW, Yarur A, McBride J, Bojic D, Lasch K, Schiffman C, Hung KE, Feagan B
Inflammatory Disease | Inflammatory Bowel Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.